Cancer Drug Resistance

cdr

Search

Hot Keywords

Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top

Editorial Board

Editor-in-Chief

Godefridus J. (Frits) Peters, PhD

gj.peters@amsterdamumc.nl

Amsterdam UMC, location VUMC, Laboratory Medical Oncology, Cancer Center, Amsterdam, The Netherlands; Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.

Research Interests: cancer biomarkers, apoptosis, lung diseases, cell culture, gene expression, pharmacokinetics, pharmacodynamics and pharmacogenetics of anticancer drugs, gastrointestinal cancers, translational research, animal models, drug metabolism and transport, influx and efflux proteins.
Contributions:
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Cancer drug resistance: a new perspective
Special Issue:
The Role of the Microbiome in Drug Resistance

Editorial Board Members

Aamir Ahmad

Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Research Interests: non-coding RNAs expression, signaling in cancer metastasis, circulating and tissue biomarkers.
Contributions:
Epigenetic basis of cancer drug resistance
Special Issue:
Epigenetic Basis of Cancer Drug Resistance
Suresh V. Ambudkar

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

Research Interests: ATP-binding cassette (ABC) drug transporters, drug resistance, membrane biochemistry, chemoresistance, transport proteins.
Yehuda G. Assaraf

Fred Wyszkowski Cancer Research Laboratory, Technion - Israel Institute of Technology, Haifa, Israel.

Research Interests: molecular mechanisms of anticancer drug resistance.
Benjamin Bonavida

Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Research Interests: apoptosis, immunotherapy resistance, cancer drug resistance.
Contributions:
Cell-mediated immune resistance in cancer
Stergios Boussios

Oncology Department, Medway NHS Foundation Trust, Kent, UK.

Research Interests: cancer treatment, cancer in pregnancy, cancer diagnostics, cancer biology, cancer biomarkers, gynaecological cancers, urological cancers, colorectal cancer, autoimmunity.
Ingolf Cascorbi

Institute of Experimental and Clinical Pharmacology, Christian Albrechts University Kiel, Hospitalstr. 4, Kiel, Germany.

Research Interests: cancer biology, pharmacokinetics, genotyping, mutation, DNA, genetics, enzymes, drug safety, pharmaceutical development, intensive care medicine.
Contributions:
Germline variants in cancer therapy
Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.

Research Interests: myelodysplastic syndromes, hematological malignancies, lymphoma, multiple myeloma, hematologic diseases, clinical hematology, blood disorders, acute myeloid leukemia, chemotherapy, leukemia, acute lymphoblastic leukemia.
Special Issue:
Research Progress on Drug Resistance in Acute Myeloid Leukemia

Papers from The SOHO (Society of Hematologic Oncology) 3rd Italian Conference
Zhe Sheng Chen

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA.

Research Interests: ABC transporters, multidrug resistance, cancer pharmacology.
William C.S. Cho

Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.

Research Interests: cancer biomarkers, drug repurposing, non-coding RNA, proteomics.
Contributions:
Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance
Jacqueline Cloos

Department of Hematology, Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Research Interests: proteasome inhibitors, minimal residual disease, clonal evolution, splicing, cellular drug addiction, hematology, drug combination studies.
Contributions:
Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication
Paul Dent

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.

Research Interests: cancer therapeutics, rational combination of drugs, molecular mechanisms, drug combinations synergize, breast, brain, liver/pancreatic cancers.
Contributions:
Kinase inhibitors: look beyond the label on the bottle
Thomas Efferth

Department of Pharmaceutical Biology, Institute of Biochemistry and Pharmacy, Johannes Gutenberg University, Staudinger Weg 5, Mainz, Germany.

Research Interests: natural product chemistry, medicinal and pharmaceutical chemistry, virtual drug screening, transcriptomics, network pharmacology, biochemistry, drug development, apoptosis, cancer biology.
Contributions:
Drug targets and resistance mechanisms in multiple myeloma
Special Issue:
Drug Resistance in Metastatic Castration-Resistant Prostate Cancer
Wafik S. El-Deiry

Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.

Research Interests: p53 tumor suppression, autophagy, cell death signaling pathways, DNA damage, TRAIL pathway, hypoxia, drug resistance, novel therapeutics, translational oncology.
Marco Falasca

Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.

Research Interests: pancreatic cancer, exosomes, lipid metabolism, membrane transporters, signal transduction, cancer invasion and metastasis, phosphoinositide signalling, cannabinoids.
Special Issue:
Treatment of Pancreatic Cancer
Carlos G. Ferreira

Oncoclinica Group, Oncoclinical Institute, Rio de Janeiro, Brazil.

Research Interests: immune microenvironment, non-small-cell lung cancer.
Liwu Fu

Department of Experimental Research (Cancer Institute), Sun Yat-sen University, Guangzhou, China.

Research Interests: ABC transporter, cancer therapy, chemotherapy resistance, multidrug resistance, immune checkpoint blockade, leukemia.
Contributions:
Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response
Special Issue:
Tumor Microenvironment and Drug Resistance
Jean-Pierre Gillet

Laboratory of Molecular Cancer Biology, Department of Biomedical Sciences, Faculty of Medicine, University of Namur, Namur, Belgium.

Research Interests: ATP-binding cassette transporters, cancer multidrug resistance mechanisms, pharmacogenomics, cancer biology, transcriptomics.
Elisa Giovannetti, PhD

Lab Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisana per la Scienza, Pisa, Italy.

Research Interests: molecular pharmacology, chemoresistance, pancreatic cancer, thoracic cancers.
Contributions:
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Targeted therapies in cancer: where are we going?

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Special Issue:
Targeted cancer therapy

Novel Targets for Therapy Resistant Pancreatic Carcinoma
William Gmeiner

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Research Interests: colorectal cancer, fluoropyrimidine, thymidylate synthase, DNA topoisomerase, aberrant signaling pathways in tumor cells.
Contributions:
Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs

Targeting DNA topoisomerases: past & future

Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations
Special Issue:
Targeting DNA Topoisomerases – Past and Future
Ivana Grivicich

Cancer Biology Laboratory, Lutheran University of Brazil, Canoas, Brazil.

Research Interests: breast cancer, colon cancer, cell culture, apoptosis.
Contributions:
Resistance mechanism to cisplatin in NCI-H460 non-small cell lung cancer cell line: investigating apoptosis, autophagy, and cytogenetic damage
Sanjay Gupta

Department of Urologic Oncology, Case Western Reserve University, Cleveland, Ohio, USA.

Research Interests: cancer chemoprevention, cancer therapeutics, drug resistance, drug repurposing, translational oncology, cancer biology, signal transduction, apoptosis, antioxidant activity, artificial intelligence, cancer biomarkers, diet nutrition and cancer, drug delivery, toxicology, epigenetics, inflammation, cancer stem cells.
Contributions:
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

Molecular insight: SERPINB3 and AR sensitivity might reduce the risk of COVID-19 infection and complications in prostate cancer patients receiving androgen-deprivation therapy

Dietary phytochemicals and their role in cancer chemoprevention

Role of prostate cancer stem-like cells in the development of antiandrogen resistance

New insights for drug resistance in metastatic castration-resistant prostate cancer

Emerging targets in cancer drug resistance
Special Issue:
Phytochemicals and Cancer Chemoprevention

Genetics and Epigenetics of Prostate Cancer: from Etiology to Treatment
Georg Hempel

Clinical Pharmacy Group, Department of Pharmaceutical and Medical Chemistry, University of Münster, Münster, Germany.

Research Interests: capillary electrophoresis, chromatography, pharmacokinetics, drug safety, oncology.
Dominique Heymann

Institut de Cancérologie de l'Ouest, Université de Nantes, Saint-Herblain, France.

Research Interests: circulating tumour cells, pathogenesis of bone sarcoma, osteoclast differentiation, metastatic process.
Contributions:
Exosomal lncRNAs: the newest promising liquid biopsy

Drug resistance in glioblastoma: are persisters the key to therapy?

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma
Peter J. Houghton

Department of Molecular Medicine, Greehey Children’s Cancer Research Institute, UT Health San Antonio, San Antonio, USA.

Research Interests: pediatric sarcomas, low-grade brain tumors, pediatric cancers of the kidney, nephroblastoma.
Contributions:
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma
Marja Jäättelä

Cell Death and Metabolism Unit, Center for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Copenhagen, Denmark.

Research Interests: autophagy, cancer progression, lysosomal, DNA, pH regulation.
Gerrit Jansen

Department of Rheumatology, Amsterdam Rheumatology and immunology Center (ARC), Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.

Research Interests: rheumatology, cancer biology and immunology, imaging and biomarkers, inflammatory diseases, antifolates, proteasome inhibitors, (multi) drug resistance.
Contributions:
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Markus Joerger

Division of Medical Oncology, University of Basel, Basel, Switzerland.

Research Interests: thoracic malignancies, clinical pharmacology, pharmacogenetics, pharmacokinetics, immunotherapy.
Michael Kahn

Department of Molecular Medicine, City of Hope's comprehensive cancer center, Duarte, CA, USA.

Research Interests: chemical genomics, Wnt signaling.
Contributions:
Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance
Ganna Kalayda

Institute of Pharmacy, University of Bonn, Bonn, Germany.

Research Interests: fluorescence microscopy, cell culture, live cell imaging, fluorescence imaging, flow cytometry, western blot analysis, cancer biology, immunofluorescence staining, intracellular trafficking, synthesis.
Hang Fai Kwok

Faculty of Health Sciences, University of Macau, Macau, China.

Research Interests: novel therapeutic antibodies development, venom-based peptide & natural biomolecule prototype drugs development, cancer biomarkers & immunotherapy markers discovery for prognostic and therapeutic validation
Lucia R. Languino

Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

Research Interests: signaling pathways, cross-talk between cell adhesion molecules, extracellular matrix proteins and growth factor receptors in vitro and in vivo systems, prostate cancer cells, signals directing distant localization, cellular and molecular characterization.
Contributions:
Methods for extracellular vesicle isolation from cancer cells
Jonathan Ledermann

UCL Cancer Institute, University College London, London, UK

Research Interests: gynaecological cancers, ovarian cancer.
Contributions:
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
Thomas Litman

Faculty of Health and Medical Sciences, Department of Immunology & Microbiology, University of Copenhagen, Copenhagen, Denmark.

Research Interests: bioinformatics, multi-omics, transcriptomics, proteomics, pharmacogenomics, metabolomics, microbiome analysis, machine learning, translational research, biomarker discovery, oncogenomics, multidrug resistance: MDR, P-glycoprotein, ABCG2, ATPase activity, transport kinetics.
Special Issue:
ABC Transporters in Multidrug-Resistant Cancer
Jose J.G. Marin

Laboratory of Experimental Hepatology and Drug Targeting, National Institute for Study of Liver and Gastrointestinal Diseases, University of Salamanca, Salamanca, Spain.

Research Interests: hepatology and drug targeting, liver and gastrointestinal diseases.
Contributions:
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
Giovanni Martinelli

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.

Research Interests: leukemia, myelodysplastic syndromes, multiple myeloma, hematologic diseases, lymphoma, blood disorders, stem cell transplantation, chemotherapy, clinical hematology, hematology.
Special Issue:
Research Progress on Drug Resistance in Acute Myeloid Leukemia

Papers from The SOHO (Society of Hematologic Oncology) 3rd Italian Conference
Cornelis J. M. Melief

Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands.

Research Interests: HLA (human leukocyte antigen), MHC, histocompatibility, immunotherapy, cancer research, clinical immunology, cancer vaccines.
Martin Michaelis

School of Biosciences, University of Kent, Canterbury, UK.

Research Interests: virology, emerging infectious diseases, apoptosis, virus, PCR, cancer cell line.
Contributions:
Drug-adapted cancer cell lines as preclinical models of acquired resistance

What really matters - response and resistance in cancer therapy
Special Issue:
Papers from the BACR Conference-Response and Resistance in Cancer Therapy

Papers from the 2nd BACR Conference "Response and Resistance in Cancer Therapy"
Hans Minderman

Department of Flow and Image Cytometry, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Research Interests: leukemia, lymphoma, imaging flow cytometry, multidrug resistance mechanisms, immunologically-based diseases, DNA in solid tumors.
Enrico Mini

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Research Interests: leukemia, antimetabolites and metal-based drug resistance, gastrointestinal cancers, cancer pharmacogenomics, pharmacogenetics.
Contributions:
“Pharmacogenetics of Cancer” - Cancer Drug Resistance special issue
Special Issue:
Pharmacogenetics of cancer
Priyabrata Mukherjee

Department of Pathology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Research Interests: programming tumor microenvironment by nanoparticles, anti-angiogenic property of inorganic nanoparticles, metabolic enzyme and angiogenesis, identification of new molecular targets using nanotechnology, nanoendocytosis, understanding cellular processes using engineered nanoparticles, metabolic enzymes in cancer.
Patrycja Nowak-Sliwinska

Molecular Pharmacology, School of Pharmaceutical Sciences (EPGL), University of Geneva, Geneva, Switzerland.

Research Interests: multi drug combinations, drug-drug interactions, acquired drug resistance, cancer organoids, cancer treatment, tumor angiogenesis, targeted therapies.
Paola Perego

Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.

Research Interests: molecular biology, p53, DNA damage, apoptosis, cytotoxicity, pharmacology, cancer cell line.
Contributions:
Tackling cisplatin resistance in ovarian cancer: what can we do?
Special Issue:
Tackling Cisplatin Resistance in Ovarian Cancer
Roger M. Phillips

School of Pharmacy, University of Huddersfield, Huddersfield, UK.

Research Interests: tumour hypoxia, cancer metabolism, hypoxia activated prodrugs, drug discovery (including phenotypic drug evaluation), drug delivery to the tumour microenvironment.
Raphael E. Pollock

Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Research Interests: sarcoma, neoplasms, neurilemmoma, gastrointestinal stromal tumors, breast neoplasms, leiomyosarcoma, neoplasm metastasis, ewing, liposarcoma, myxoid, liposarcoma.
Chiara Riganti

Department of Oncology, University of Torino, Torino, Italy.

Research Interests: chemo-immunoresistant tumor models, lung cancer, prostate cancer, breast cancer, malignant pleural mesothelioma, glioblastoma multiforme, multiple myeloma.
Contributions:
Overcoming drug resistance in glioblastoma: new options in sight?
Special Issue:
New challenges in overcoming chemoresistance in Glioblastoma
Jose Antonio Rodriguez

Department of Genetics, Physical Anthropology and Animal Physiology (School of Medicine) of the University of the Basque Country (UPV/EHU), Basque Country, Spain.

Research Interests: molecular mechanisms of malignant transformation, protein ubiquitination, nucleocytoplasmic transport.
Contributions:
Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer

Targeted therapies in cancer: where are we going?
Special Issue:
Targeted cancer therapy
José Rueff

Nova Medical School (NMS), Universidade Nova de Lisboa/Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal.

Research Interests: genetics, bacterial cell culture, immunohistochemistry, biochemistry, genomics, PCR, gene expression, cell culture, DNA, cancer biology.
Contributions:
MicroRNAs and cancer drug resistance: over two thousand characters in search of a role

Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance
Afshin Samali

Apoptosis Research Centre, National University of Ireland, Galway, Ireland.

Research Interests: apoptosis, endoplasmic reticulum, UPR signaling in cancer, IRE1, PERK, drug discovery, biomarker discovery.
Gautam Sethi

Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Research Interests: cancer, cellular and molecular mechanisms, diagnostics and therapeutics, gastrointestinal cancer.
John Seymour

Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Australia.

Research Interests: haematology, aggressive lymphoma, acute leukemia, myelodysplasia.
Contributions:
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
Xiang-Yang Shi

College of Chemistry, Chemical Engineering and Biotechnology, Donghua Univeristy, Shanghai, China.

Research Interests: Development of organic/inorganic hybrid nanoplatforms and microfluidic platforms for sensing, imaging, and theranostic applications, in particular for precision cancer imaging and therapy.
Special Issue:
Nanotechnology Applied to Overcome Tumor Drug Resistance
Alexander Sparreboom

Division of Pharmaceutics & Pharmaceutical Chemistry College of Pharmacy, The Ohio State University, Columbus, OH, USA.

Research Interests: platinum-based drugs, tyrosine-kinase inhibitors, P-glycoprotein, cancer chemotherapy, sensitivity analysis, clinical pharmacokinetics.
Rakesh K. Srivastava

Stanley S. Scott Cancer Center, and Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Research Interests: apoptosis, cell signaling and human diseases, molecular mechanisms, stem cells and human diseases, nutrition, diet and cancer.
Gary S. Stein

Department of Biochemistry, University of Vermont Larner College of Medicine, Burlington, VT, USA.

Research Interests: breast cancer stem cells, genetic and epigenetic of cancer.
Ulrike Stein

Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité – Universitätsmedizin und Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.

Research Interests: key drivers of metastasis, MACC1, S100A4, cancer cell signaling, cancer metastasis, drug discovery.
Chunxia Su

School of Medicine, Tongji University; Deputy Director, Medical Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China.

Research Interests: non-small cell lung cancer, lung cancer, tumor microenvironment, Immunotherapy.
Contributions:
Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Immunotherapy resistance of lung cancer

Emerging insights to lung cancer drug resistance
Special Issue:
Lung Cancer Drug Resistance

Lung Cancer Drug Resistance: A New Step Forward
Haruhiko Sugimura

Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Research Interests: cancer biology, genetics, genotyping, cell biology, microscopy, hepatocellular carcinoma, pharmacology, immunohistochemistry, DNA, mutation.
Shi-Yong Sun

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.

Research Interests: regulation of death receptors, TRAIL receptors, small therapeutic molecules, drug-induced apoptosis, Akt/mTOR signaling, cancer therapy, EGFR inhibitors, acquired resistance, lung cancer.
Special Issue:
Lung Cancer Drug Resistance
Vladimir P. Torchilin

Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA.

Research Interests: drug delivery, drug targeting, nanomedicine, liposomes, micelles, experimental cancer therapy.
Special Issue:
Overcome Cancer Drug Resistance by Nano-carrier Drug Delivery System
Fatih M. Uckun

Department of Developmental Therapeutics, Immunology, and Integrative Medicine, Drug Discovery Institute, Ares Pharmaceuticals, St. Paul, MN, USA.

Research Interests: immunobiology, immunooncology, systemic inflammation, hematologic malignancies, nanotechnology.
Contributions:
Cancer drug resistance in multiple myeloma

Wilms’ tumor gene (WT1) is strongly expressed in high-risk subsets of pediatric acute lymphoblastic leukemia

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
Special Issue:
Drug Targets and Resistance Mechanisms in Multiple Myeloma

Contemporary Treatment Strategies for Adolescents and Young Adults with Cancer
Takanori Ueda

Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Research Interests: leukemia, diffuse large B‐cell lymphoma.
Brian A. Van Tine

Department of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.

Research Interests: soft tissue and bone sarcomas, human-in-mouse sarcoma models, amino acid deprivation therapies, metabolic deficiencies in sarcoma, phase 1 clinical trials.
Contributions:
Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers

PHGDH as a mechanism for resistance in metabolically-driven cancers

Immune checkpoint inhibitor resistance in soft tissue sarcoma
Special Issue:
Advanced Research of Drug Resistance in Soft Tissue and Bone Sarcoma
Robert C.A.M. van Waardenburg

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.

Research Interests: DNA repair proteins, cellular response to chemotherapy, protein-protein interactions, post-translational modification by ubiquitin and SUMO, sulfotransferases.
Contributions:
Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts

Targeting DNA repair pathways to overcome cancer drug resistance

Sphingolipid metabolism and drug resistance in ovarian cancer

Targeting DNA topoisomerases: past & future
Special Issue:
Targeting DNA Topoisomerases – Past and Future

Advances in DNA Damage & Repair and Cancer Drug Resistance
Erik A. C. Wiemer

Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.

Research Interests: cancer biology, biomarkers; non-coding RNAs, soft tissue sarcomas, lung cancer, ovarian cancer.
Takahiro Yamauchi

Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Research Interests: hematologic malignancies, nucleoside analogs, tyrosine kinase inhibitors, bcl2 inhibitors, antibodies, DNA repair, and pharmacology.
Nadia Zaffaroni

Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Research Interests: telomerase, prostatic neoplasms, melanoma, cisplatin, apoptosis, neoplasms.

Former Editorial Board Member

Joseph R. Bertino

Departments of Pharmacology and Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. (Died October 11, 2021 (aged 91))

Research Interests: cancer biology, lymphomas, antimetabolites.
Special Issue:
Research Progress on Drug Resistance in Lymphomas

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties